Novartis AG $NVS Stock Holdings Lifted by Royal Bank of Canada

Royal Bank of Canada increased its holdings in Novartis AG (NYSE:NVS) by 7.1% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 618,710 shares of the company’s stock after buying an additional 40,788 shares during the period. Royal Bank of Canada’s holdings in Novartis were worth $94,508,000 as of its most recent filing with the SEC.

Other institutional investors have also modified their holdings of the company. Archer Investment Corp lifted its holdings in Novartis by 93.0% in the first quarter. Archer Investment Corp now owns 166 shares of the company’s stock worth $25,000 after acquiring an additional 80 shares during the last quarter. Arlington Trust Co LLC bought a new position in shares of Novartis during the fourth quarter valued at approximately $25,000. CrossGen Wealth LLC bought a new position in shares of Novartis during the fourth quarter valued at approximately $28,000. Bank of Jackson Hole Trust raised its position in shares of Novartis by 425.0% during the 4th quarter. Bank of Jackson Hole Trust now owns 231 shares of the company’s stock worth $32,000 after purchasing an additional 187 shares during the period. Finally, Nalls Sherbakoff Group LLC acquired a new stake in shares of Novartis during the 4th quarter worth approximately $34,000. Institutional investors own 13.12% of the company’s stock.

Analysts Set New Price Targets

NVS has been the subject of a number of analyst reports. Citigroup restated a “buy” rating on shares of Novartis in a research report on Wednesday, July 22nd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Novartis in a research report on Friday, July 24th. Seven investment analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $141.20.

Novartis Trading Down 1.4%

NYSE:NVS opened at $156.18 on Friday. The stock has a market cap of $298.01 billion, a price-to-earnings ratio of 23.56, a PEG ratio of 2.71 and a beta of 0.45. The company has a debt-to-equity ratio of 0.89, a quick ratio of 0.67 and a current ratio of 0.86. Novartis AG has a 1 year low of $112.34 and a 1 year high of $170.46. The business has a fifty day moving average of $152.66 and a 200-day moving average of $152.72.

Novartis (NYSE:NVS) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $2.41 earnings per share for the quarter. The business had revenue of $14.95 billion for the quarter. Novartis had a net margin of 23.29% and a return on equity of 38.56%. Equities analysts predict that Novartis AG will post 8.85 earnings per share for the current year.

About Novartis

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.